US 12,128,214 B2
Intelligent drug delivery system
Arnold Chase, West Hartford, CT (US)
Filed by Arnold Chase, West Hartford, CT (US)
Filed on May 7, 2021, as Appl. No. 17/314,306.
Application 17/314,306 is a continuation in part of application No. 16/593,020, filed on Oct. 4, 2019, granted, now 11,000,647.
Prior Publication US 2021/0260284 A1, Aug. 26, 2021
Int. Cl. A61M 5/172 (2006.01); A61B 5/00 (2006.01); A61B 5/11 (2006.01); A61M 5/142 (2006.01); G06F 1/16 (2006.01); G16H 20/17 (2018.01)
CPC A61M 5/1723 (2013.01) [A61B 5/1118 (2013.01); A61B 5/4839 (2013.01); A61M 5/14248 (2013.01); A61M 5/172 (2013.01); G06F 1/163 (2013.01); G16H 20/17 (2018.01); A61B 2562/0219 (2013.01); A61M 5/14244 (2013.01); A61M 2205/3327 (2013.01); A61M 2205/52 (2013.01); A61M 2230/63 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An intelligent drug delivery system comprising:
a device body;
an accelerometer sensor arranged in or on the device body and configured to output multi-axis motion data based on detected multi-axis motion and acceleration;
a gyroscopic pitch sensor arranged in or on the device body and configured to output orientation data based on detected orientation;
a controller in communication with the accelerometer sensor and the gyroscopic pitch sensor, the controller being arranged to be worn by a user;
wherein, based on the multi-axis motion data and/or the orientation data, the controller is configured to determine positional movements of the device body, a multi-axial speed and acceleration of movement of the device body, linger times of the device body, and/or a multi-axial cadence of movement of the device body;
wherein the controller is configured to generate a pump instruction signal based on the determined multi-axial movement of the device body, multi-axial speed and acceleration of the device body, the linger times of the device body, and/or the multi-axial cadence of movement of the device body, the pump instruction signal including an instruction to change or suspend a delivery rate of a pharmacological material to achieve a daily dosage of the pharmacological material;
wherein the pharmacological material is configured to treat one or more abnormal movement symptoms of Parkinson's disease; and
wherein the controller is configured to autonomously dynamically determine whether adjustment to the daily dosage is needed and autonomously dynamically adjust the daily dosage in a closed-loop manner between the sensors arranged in or on the device body and the controller, without input of a dosage change, based on a current physically detected Parkinson's disease symptom intensity level or range of the user determined by the controller in order to optimize the daily dosage to achieve a minimum level consistent with abnormal motion control of the user.